AbbVie, a biopharmaceutical company, said pre-market Tuesday it has formed a collaboration with Principia Biopharma, a clinical-stage biopharmaceutical company, for the development of oral immunoproteasome inhibitors. Financial terms were not disclosed.
The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology. “The combination of AbbVie’s world-class expertise in immunology drug development with Principia’s innovative approach to immunoproteasome inhibitors may offer patients a new class of therapies to treat serious and chronic conditions,” said Lisa Olson, vice president of immunology research at AbbVie. The collaboration contemplates the creation and development of orally bioavailable, selective inhibitors of the immunoproteasome subunits to target autoimmunity. AbbVie and Principia will collaborate on research and pre-clinical studies.